The Use of Protease Inhibitors in Pregnancy

Maternal and Fetal Considerations

Elaine Duryea, Fiona Nicholson, Sara Cooper, Scott Roberts, Vanessa Rogers, Donald McIntire, Jeanne Sheffield, Robert Stewart

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background. Previous studies examining protease inhibitor use in pregnancy and the rate of preterm and small-for-gestational-age infants have yielded conflicting results. Methods. This was a retrospective study of HIV-infected women who delivered singleton infants at our institution between 1984 and 2014. Women with protease inhibitor use were compared to women on regimens without a protease inhibitor as well as those who received no antepartum antiretroviral therapy. Infants were considered preterm if less than 37 completed weeks of gestation and small-for-gestational-age if less than 10th percentile. Results. During the study period 1,004 pregnancies met inclusion criteria. Of those, 597 received a protease inhibitor as part of their regimen, 230 ART without a protease inhibitor, and 177 no ART. There was no difference in the rate of preterm birth between groups who received ART with or without a protease inhibitor, 14% versus 13%. There was no difference in the rate of small-for-gestational-age infants between the three groups. Use of a protease inhibitor was associated with a greater fall in viral load during pregnancy, p

Original languageEnglish (US)
Article number563727
JournalInfectious Diseases in Obstetrics and Gynecology
Volume2015
DOIs
StatePublished - 2015

Fingerprint

Protease Inhibitors
Mothers
Pregnancy
Small for Gestational Age Infant
Premature Birth
Pregnancy Rate
Viral Load
Gestational Age
Retrospective Studies
HIV

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Infectious Diseases
  • Dermatology

Cite this

@article{62fb19b9160d4f6f87f2af8697f52aee,
title = "The Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations",
abstract = "Background. Previous studies examining protease inhibitor use in pregnancy and the rate of preterm and small-for-gestational-age infants have yielded conflicting results. Methods. This was a retrospective study of HIV-infected women who delivered singleton infants at our institution between 1984 and 2014. Women with protease inhibitor use were compared to women on regimens without a protease inhibitor as well as those who received no antepartum antiretroviral therapy. Infants were considered preterm if less than 37 completed weeks of gestation and small-for-gestational-age if less than 10th percentile. Results. During the study period 1,004 pregnancies met inclusion criteria. Of those, 597 received a protease inhibitor as part of their regimen, 230 ART without a protease inhibitor, and 177 no ART. There was no difference in the rate of preterm birth between groups who received ART with or without a protease inhibitor, 14{\%} versus 13{\%}. There was no difference in the rate of small-for-gestational-age infants between the three groups. Use of a protease inhibitor was associated with a greater fall in viral load during pregnancy, p",
author = "Elaine Duryea and Fiona Nicholson and Sara Cooper and Scott Roberts and Vanessa Rogers and Donald McIntire and Jeanne Sheffield and Robert Stewart",
year = "2015",
doi = "10.1155/2015/563727",
language = "English (US)",
volume = "2015",
journal = "Infectious Diseases in Obstetrics and Gynecology",
issn = "1064-7449",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The Use of Protease Inhibitors in Pregnancy

T2 - Maternal and Fetal Considerations

AU - Duryea, Elaine

AU - Nicholson, Fiona

AU - Cooper, Sara

AU - Roberts, Scott

AU - Rogers, Vanessa

AU - McIntire, Donald

AU - Sheffield, Jeanne

AU - Stewart, Robert

PY - 2015

Y1 - 2015

N2 - Background. Previous studies examining protease inhibitor use in pregnancy and the rate of preterm and small-for-gestational-age infants have yielded conflicting results. Methods. This was a retrospective study of HIV-infected women who delivered singleton infants at our institution between 1984 and 2014. Women with protease inhibitor use were compared to women on regimens without a protease inhibitor as well as those who received no antepartum antiretroviral therapy. Infants were considered preterm if less than 37 completed weeks of gestation and small-for-gestational-age if less than 10th percentile. Results. During the study period 1,004 pregnancies met inclusion criteria. Of those, 597 received a protease inhibitor as part of their regimen, 230 ART without a protease inhibitor, and 177 no ART. There was no difference in the rate of preterm birth between groups who received ART with or without a protease inhibitor, 14% versus 13%. There was no difference in the rate of small-for-gestational-age infants between the three groups. Use of a protease inhibitor was associated with a greater fall in viral load during pregnancy, p

AB - Background. Previous studies examining protease inhibitor use in pregnancy and the rate of preterm and small-for-gestational-age infants have yielded conflicting results. Methods. This was a retrospective study of HIV-infected women who delivered singleton infants at our institution between 1984 and 2014. Women with protease inhibitor use were compared to women on regimens without a protease inhibitor as well as those who received no antepartum antiretroviral therapy. Infants were considered preterm if less than 37 completed weeks of gestation and small-for-gestational-age if less than 10th percentile. Results. During the study period 1,004 pregnancies met inclusion criteria. Of those, 597 received a protease inhibitor as part of their regimen, 230 ART without a protease inhibitor, and 177 no ART. There was no difference in the rate of preterm birth between groups who received ART with or without a protease inhibitor, 14% versus 13%. There was no difference in the rate of small-for-gestational-age infants between the three groups. Use of a protease inhibitor was associated with a greater fall in viral load during pregnancy, p

UR - http://www.scopus.com/inward/record.url?scp=84947474641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947474641&partnerID=8YFLogxK

U2 - 10.1155/2015/563727

DO - 10.1155/2015/563727

M3 - Article

VL - 2015

JO - Infectious Diseases in Obstetrics and Gynecology

JF - Infectious Diseases in Obstetrics and Gynecology

SN - 1064-7449

M1 - 563727

ER -